文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

来那卡帕韦：如果能公平应用，它可能会改变美洲地区艾滋病预防的格局。

Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.

作者信息

Cantos Valeria D, Ramírez Brenda Crabtree, Kelley Colleen F, Rio Carlos Del, Grinsztejn Beatriz

机构信息

Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, USA.

Grady Health System, Atlanta, USA.

出版信息

Lancet Reg Health Am. 2025 Jun 10;47:101146. doi: 10.1016/j.lana.2025.101146. eCollection 2025 Jul.

DOI:10.1016/j.lana.2025.101146
PMID:40546885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12178911/
Abstract

Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake disparities. In this viewpoint, we summarize the current efforts to scale up lenacapavir access globally and the necessary steps to include Latin America in these endeavours.

摘要

来那卡帕韦是首个长效衣壳抑制剂，在预防艾滋病毒方面具有近100%的疗效。因此，它有可能遏制拉丁美洲艾滋病毒发病率的上升，该地区国家内部和国家之间的暴露前预防（PrEP）使用情况存在明显差异。在本文观点中，我们总结了目前在全球范围内扩大来那卡帕韦可及性的努力，以及将拉丁美洲纳入这些努力的必要步骤。

相似文献

[1]
Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.

Lancet Reg Health Am. 2025-6-10

[2]
Incentives for preventing smoking in children and adolescents.

Cochrane Database Syst Rev. 2017-6-6

[3]
Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.

Lancet Glob Health. 2024-2

[4]
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Cochrane Database Syst Rev. 2008-7-16

[5]
Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial of Systems Navigator-Delivered Integrated Prevention Package (HPTN 112-NJIRA Study).

JMIR Res Protoc. 2025-6-18

[6]
CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases.

Top Antivir Med. 2025-5-21

[7]
Development and Pilot Testing of an Addiction Clinic-Based Pre-Exposure Prophylaxis Uptake and Adherence Intervention for Women with Substance Use Disorders: Protocol for a Pilot Randomized Trial.

JMIR Res Protoc. 2025-5-23

[8]
Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review.

JMIR Public Health Surveill. 2022-6-7

[9]
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Cochrane Database Syst Rev. 2020-10-19

[10]
Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients.

Cochrane Database Syst Rev. 2018-6-25

本文引用的文献

[1]
Lenacapavir for Human Immunodeficiency Virus (HIV) Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.

Clin Infect Dis. 2025-4-9

[2]
Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status.

Infez Med. 2025-3-1

[3]
Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.

J Gen Intern Med. 2025-2-11

[4]
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

Clin Infect Dis. 2025-1-28

[5]
Long-Acting HIV Medicines and the Pandemic Inequality Cycle - Rethinking Access.

N Engl J Med. 2025-1-2

[6]
Why is roll-out of long-acting PrEP agents so slow?

Curr Opin HIV AIDS. 2025-1-1

[7]
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.

N Engl J Med. 2025-4-3

[8]
Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023.

JAMA. 2024-11-12

[9]
Lenacapavir to prevent HIV infection: current prices versus estimated costs of production.

J Antimicrob Chemother. 2024-11-4

[10]
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

N Engl J Med. 2024-10-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索